Aerpio Pharmaceuticals, Inc. announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Jefferies 2018 Global Healthcare Conference.
CINCINNATI--(BUSINESS WIRE)-- Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the Jefferies 2018 Global Healthcare Conference on Friday, June 8, 2018 at 1:30 p.m. Eastern Time in New York, NY. Dr. Hoffmann will provide a corporate overview and business update.
The presentation will be webcast live and may be accessed by visiting Aerpio’s website at http://ir.aerpio.com/.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company’s lead compound, AKB‐9778, is a small molecule activator of the Tie2 pathway and is in clinical development for the treatment of non-proliferative diabetic retinopathy. For more information please visit www.aerpio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180531005453/en/
Contacts
Aerpio Pharmaceuticals, Inc.
Michael Rogers, 513-985-1958
Chief Financial Officer
Source: Aerpio Pharmaceuticals, Inc.
